SCHEMBL367096

SCHEMBL367096

O=C(O)C1(O)CCCc2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C1 Q04828 1/20 0.47
HDAC9 Q9UKV0 1/20 0.46
AKR1B1 P15121 1/20 0.44
KDM1A O60341 2/20 0.44
SIGMAR1 Q99720 2/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
DRD2 P14416 1/20 0.41
TSHR P16473 1/20 0.41
NFKB1 P19838 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTR2B P41595 1/20 0.41
MTOR P42345 1/20 0.41
HCAR2 Q8TDS4 1/20 0.41
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1981942 0.89 HDAC9 (0.49) AKR1C1HDAC9KDM1ASIGMAR1TP53
SCHEMBL11393939 0.84 KDM1A (0.46) HDAC9AKR1B1KDM1ASIGMAR1MEN1
SCHEMBL16836079 0.80 KDM1A (0.43) HDAC9AKR1B1KDM1AMEN1KMT2A
SCHEMBL6810390 0.80 AKR1C1 (0.39) AKR1C1KDM1ATP53NFKB1MEN1
SCHEMBL687495 0.80 AKR1C1 (0.48) AKR1C1HDAC9AKR1B1KDM1ASIGMAR1
SCHEMBL30219063 0.80 AKR1C1 (0.48) AKR1C1HDAC9AKR1B1KDM1ASIGMAR1
SCHEMBL6580393 0.78 KDM1A (0.49) KDM1ASIGMAR1
SCHEMBL8944132 0.77 AKR1C1 (0.46) AKR1C1HDAC9AKR1B1KDM1ASIGMAR1
SCHEMBL2999169 0.77 AKR1C1 (0.46) AKR1C1HDAC9AKR1B1KDM1ASIGMAR1
SCHEMBL4851505 0.77 KDM1A (0.50) AKR1C1HDAC9AKR1B1KDM1AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4404271-A RESIN CAMPATIBLE ORIENT CHEMICAL INDUSTRIES, LTD. (JP) 1983-09-13 US claimed
US-20140243334-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
WO-2012012320-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENIUM PHARMACEUTICALS, INC. (US) 2012-01-26 WO disclosed
US-20120015942-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-01-19 US disclosed
EP-1012140-B1 NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS ASTRAZENECA AB (SE) 2004-09-29 EP disclosed
US-6576657-B2 Nitrogen containing heterocyclic compounds useful as anticoagulants ASTRAZENECA AB (SE) 2003-06-10 US disclosed
US-20020022612-A1 New amidino derivatives and their use as thrombin inhibitors ASTRAZENECA AB 2002-02-21 US disclosed
US-6265397-B1 Amidino derivatives and their use as thrombin inhibitors ASTRAZENECA AB (SE) 2001-07-24 US disclosed
US-4404271-A RESIN CAMPATIBLE ORIENT CHEMICAL INDUSTRIES, LTD. (JP) 1983-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015942-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC2 AKR1C1 782/4885HDAC9 9/4885AKR1B1 851/4885
US-20140243334-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF HDAC6, H1-3, H1-5 AKR1C1 548/4885HDAC9 15/4885AKR1B1 527/4885
US-20020022612-A1 New amidino derivatives and their use as thrombin inhibitors SERPINC1, SERPINE1, SERPINB1 AKR1C1 2589/4885HDAC9 2098/4885AKR1B1 1664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.